What is Talphera?
Headquartered in San Mateo, California, Talphera, Inc. operates as a specialty pharmaceutical firm dedicated to the development and commercialization of innovative therapies designed for use in controlled, medically supervised settings. The company's portfolio is anchored by Niyad, a lyophilized formulation of nafamostat currently under an investigational device exemption for use as an anticoagulant in extracorporeal circuits. Beyond its lead candidate, Talphera is actively advancing LTX-608, a versatile therapeutic candidate with potential applications in treating acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. Furthermore, the company maintains a focus on hospital-based procedural medicine through its pre-filled syringe programs, including Fedsyra and PFS-02. This diversified approach positions Talphera as a critical player in the intersection of pharmaceutical innovation and acute care medical technology.
How much funding has Talphera raised?
Talphera has raised a total of $46M across 2 funding rounds:
Stock/Share Issuance
$29M
Stock/Share Issuance
$17M
Stock/Share Issuance (2025): $29M, investors not publicly disclosed
Stock/Share Issuance (2025): $17M, investors not publicly disclosed
Key Investors in Talphera
Undisclosed Institutional Investor
An undisclosed institutional entity providing strategic capital to support the advancement of clinical-stage pharmaceutical development.
Undisclosed Private Equity Firm
A private equity participant focused on long-term value creation within the specialty healthcare and medical device sectors.
Undisclosed Strategic Partner
A strategic investor specializing in the commercialization of therapeutic assets for medically supervised environments.
What's next for Talphera?
With the recent $17M injection, Talphera is poised to prioritize the regulatory advancement of its lead assets. The strategic roadmap focuses on the successful commercialization of Niyad, while simultaneously de-risking the clinical development of LTX-608. Investors should monitor the company's progress regarding its investigational device exemption status and the potential market entry of its pre-filled syringe portfolio. As the firm continues to refine its operational focus, the primary objective remains the delivery of high-value therapeutic interventions that address significant unmet needs in acute care settings. The company's ability to execute on these clinical objectives will be the primary driver of shareholder value in the coming fiscal periods.
See full Talphera company page
